Posted by Michael Wonder on 18 Oct 2017
Economic evaluation of personalised medicine: a call for real-world data
18 October 2017 - In the last decade, we have witnessed a change in healthcare management, with ‘personalised medicine’ as the new paradigm.
Also referred to as ‘individualized’, ‘stratified’, or ‘precision’ medicine, this new paradigm for the diagnosis and management of disease aims to tailor protocols and treatments to the personal and medical characteristics of patients. Personalised medicine (PM) has rapidly penetrated European Union health care systems.
Although there is no universally accepted definition, the Horizon 2020 Advisory Group of the EU has defined PM as “a medical model using characterisation of individuals’ phenotypes and genotypes (e.g., molecular profiling, medical imaging, lifestyle data) for tailoring the right therapeutic strategy for the right person at the right time, and/or to determine the predisposition to disease and/or to deliver timely and targeted prevention”.
